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Summary We have investigated P-glycoprotein (P-gp) expression in samples of primary breast cancer from 29
patients before therapy. We employed immunohistochemical techniques using two monoclonal antibodies
(C219 and MRK16) and an indirect alkaline phosphatase method. Heterogeneous expression in epithelial cells
was detected with both C219 (21 of 29) and MRK16 (16 of 29). A surprising finding was P-glycoprotein
expression in stromal cells with both C219 (26 of 29) and MRK16 (12 of 29). Our results suggest that
significant levels of P-glycoprotein expression may be present in breast cancer before exposure to drugs
associated with multidrug resistance.
One of the major problems in the treatment of cancer is the
development of resistance to cytotoxic drugs. One mechanism
of resistance, multidrug resistance (MDR), has been exten-
sively studied in both animal and human cell lines in vitro
(Biedler & Riehm, 1970; Fojo et al., 1985), and is charac-
terised by cross-resistance to a variety of structurally un-
related drugs following exposure to only one of them. The
drugs involved in the MDR phenotype include anthracyclines
and Vinca alkaloids (Moscow & Cowan, 1988). The MDR
phenotype is associated with increased expression of the
MDR gene, mdr-1 (Roninson et al., 1986), which encodes a
transmembrane glycoprotein of 170,000 daltons (Riordan et
al., 1985). This glycoprotein, termed P-glycoprotein (P-gp), is
present in many MDR cell lines, but not in the correspond-
ing wild types (Juliano & Ling, 1976) and is thought to act as
an energy-dependent drug efflux pump (Chen et al., 1986).
However, the role of the mdr-1 gene and P-gp in clinical drug
resistance is not yet clear.
Human mdr-1 expression in a variety of normal tissues and
tumours has been studied by measurement of mdr-1 mRNA
(Fojo et al., 1987). High levels were found in normal adrenal,
kidney and colon and in tumours arising from these organs.
Two previous studies have examined mdr-1 expression in
breast cancer by measuring mdr-1 mRNA. In one series there
was no expression (Merkel et al., 1989) while low levels were
found in 15% of tumours in the other series (GoMOstein et al.,
1989). In contrast, we have previously shown significant
levels ofmdr-1 mRNA in a series of untreated primary breast
cancers (Keith et al., 1990) with a wide variation in expres-
sion between different tumours. These different results may
be explained by heterogeneity of expression of P-gp in breast
cancer. Although our study suggests that the mdr-1 gene is
expressed in a proportion of breast cancers, the detection of
mRNA in a homogenised tumour sample does not tell us
which cells are expressing mdr-I or how these cells are dis-
tributed within the tumour. In addition this technique may
not be sensitive enough to detect a small population of MDR
cells. The use ofmonoclonal antibodies to P-gp and immuno-
cytochemistry (ICC) can circumvent these problems by allow-
ing detection of P-gp in single, or small numbers of cells
while allowing distribution throughout the various cell types
to be examined.
Monoclonal antibodies have already been used to detect
P-gp expression in several human tumours. C219, which
reacts with an internal epitope of P-gp, has revealed P-gp
expression in acute non-lymphoblastic leukaemia (Ma et al.,
1987) as well as lung and ovarian carcinomas (Volm et al.,
1989). Moreover, C219 has confirmed P-gp expression in
both untreated and treated breast cancers (Salmon et al.,
1989; Schneider et al., 1989). In addition MRK16, which
reacts with an external epitope of P-gp, has detected P-gp
expression by ICC in untreated lung and breast cancer
(Sugawara et al., 1988).
The use of ICC has therefore suggested that P-gp may be
expressed in a small proportion of breast cancers although
the number of tumours sampled is often small and may not
be representative of all breast cancers. If present in breast
cancer we need to establish which cells express P-gp and
whether these cells are present prior to treatment with MDR
drugs or whether they arise following exposure to them.
We have therefore further investigated P-gp expression in
29 primary breast cancers (all untreated) by ICC on tumour
frozen sections using two monoclonal antibodies (C219 and
MRK16) and an indirect alkaline phosphatase method.
Materials and methods
Human tissue
All breast biopsies were obtained from patients undergoing
breast surgery at the Royal Infirmary, Glasgow from 1984 to
1986. All biopsies were snap frozen in liquid nitrogen and
stored at -70°C until sectioning.
Cell line
As a positive control with each specimen we used cytospin
preparations of the small cell carcinoma of lung line H69/
LX10. This cell line was derived from the parent cell line
NCI H69 by chronic exposure to adriamycin (to a final
concentration of 1 Zg ml-') and was a gift from Dr P. Twen-
tyman (MRC Clinical Oncology and Radiotherapeutics Unit,
Cambridge). It has previously been shown to have high
expression of P-glycoprotein (Plumb et al., 1990).
Immunohistochemistry
Cryostat sections of 5ym were cut from each biopsy, air
dried for 1 h, then fixed in acetone for 10 min at room
temperature. They were then stained using an indirect
immuno-alkaline phosphatase technique, incubating sections
with a range of primary mouse monoclonal antibodies for
2 h (see below). The secondary antibody was a rabbit anti-
mouse immunoglobulin conjugated to alkaline phosphatase
(Dako, High Wycombe, Bucks., UK) and used at a working
dilution of 1:20 for 45 min. The colour reaction was
developed using a substrate solution based on fast red pro-
ducing a red reaction in positive cells, then sections were
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counterstained with haematoxylin. This technique was chosen
as we found it to be more sensitive than using immunoperox-
idase and furthermore endogenous alkaline phosphatase
activity can easily be blocked unlike endogenous peroxidase
activity.
In negative controls an irrelevant monoclonal antibody
(Clonab LN-C, Biotest, UK) was substituted for the primary
antibody. For the detection of P-glycoprotein antibodies
C219 (Kartner et al., 1985; obtained from CIS UK Ltd, High
Wycombe, Bucks.) and MRK16 (Hamada & Tsuruo, 1986; a
gift from T. Tsuruo) were used, both at a final concentration
of 10 tg mlP'. Selected cases were also stained using
CAM 5.2 (Becton Dickinson, California, USA), AE1/AE3
(ICN, High Wycombe, Bucks., UK) to detect cytokeratins
and with antibody to vimentin (Boehringer, Lewes, East
Sussex. UK).
Figure I Cytospin preparations of H69/LXI0 stained with C219 a, and MRK16 b. The bar in a represents 100 um. All other
photomicrographs are at the same magnification, except g where the bar represents 10 m. Staining of epithelial c and stromal e
cells with C219 in sections ofprimary breast cancer. g shows staining with C219 in an isolated epithelial cell. d and f show staining
with MRK16 in epithelial and stromal cells respectively in primary breast cancers. h shows a section of primary breast cancer
stained with an antibody to vimentin.760 G.C. WISHART et al.
Assessment ofP-glycoprotein expression
All tumour frozen sections were examined by an experienced
pathologist (J.J.G.) and an estimation of the percentage of
cells showing positive staining was made. This estimate of
positive cells in a representative section from each patient
was then allocated to one of four bands (0%, 1-9%,
10-49%, 50-100%). We did not attempt to grade intensity
as this can vary between experiments and cells were normally
clearly positive or negative. A section of each tumour was
stained with haematoxylin and eosin to confirm that tumour
was present in that section.
Results
Positive control
Both C219 and MRK16 stained the positive control H69/
LX10. Staining with C219 (Figure la) was more intense than
with MRK16 (Figure lb).
Primary breast cancers
Twenty-nine breast cancers (all untreated) were incubated
with both C219 and MRK16. The results from all patients
are summarised in Table I. C219 revealed a heterogeneous
pattern of staining in epithelial cells (Figure lc) in 21 of 29
tumours. However, in 26 of the patients C219 showed mark-
ed staining in stromal cells (Figure le). Furthermore, the
proportion of positively stained stromal cells was notably
higher than that for the epithelial cells. Although the number
of cells staining with MRK16 was less than that with C219,
the same pattern was observed with expression in both
epithelial (16 of 29) and stromal (12 of 29) cells (Table I).
Immunostaining in epithelial cells, with both antibodies,
occurred in either single cells (Figure 1g) or occasionally
groups of cells (Figure ld). In the presence of irrelevant
antibody no areas of staining at all were visible.
Table I Percentage of cells expressing P-glycoprotein, detected by
mAbsC219 and MRK16andimmunocytochemistry, in 29patientswith
primary breast cancer
Patient
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
Epithelial cells
C219 MRKJ6
0 <5
<5 10
5 0
<5 0
<5 0
10 0
0 0
10 <5
0 0
<5 <5
<5 <5
5 <5
<5 <5
5 <5
<5 5
0 0
<5 <5
5 0
<5 5
10 0
0 0
40 30
0 0
5 <5
0 0
<5 <5
<5 <5
0 5
<5 0
Stromal cells
C219
75
40
90
50
50
0
40
60
15
80
90
25
80
10
90
50
5
60
30
30
0
40
0
40
80
90
90
20
60
MRK16
<5
15
<5
0
0
0
0
0
0
0
20
0
5
0
0
0
<5
0
0
0
<5
0
0
S
50
<5
0
5
5
Table II Number ofpatients allocated to each groupaccording to the
percentage ofpositively stained cells, both epithelial and stromal, with
two monoclonal antibodies C219 and MRK16
Number ofpatients
Proportion of cells Epithelial cells Stromal cells
stainedpositive (%) C129 MRK16 C219 MRK16
0 8 13 3 17
1-9 17 4 1 9
10-49 4 2 10 2
50-100 0 0 15 1
The stromal cells which stained positive were spindle-
shaped cells with elongated nuclei (see Figure le and f).
These cells were confirmed as non-epithelial by positive stain-
ing with a monoclonal antibody against vimentin (Figure lh),
an intermediate filament protein present in cells of mesen-
chymal origin, and the absence of staining when incubated
with the anti-cytokeratin Cam 5.2 (not shown), a monoclonal
antibody which reacts with most adenocarcinomas. Further-
more, no staining of stromal cells was observed with the
anti-cytokeratin AEl/3 (results not shown).
Discussion
In the present study we have examined P-glycoprotein ex-
pression by immunohistochemistry in 29 primary breast can-
cers (all untreated) using two monoclonal antibodies (C219
and MRK16) and an indirect alkaline phosphatase method.
Our study clearly shows that P-glycoprotein immunoreac-
tivity, detected by C219 and MRK16, can be demonstrated
in a proportion of untreated primary breast cancers. Im-
munostaining was heterogeneous and interestingly appeared
in epithelial and non-epithelial cells (Figure lc-f). We have
confirmed that the non-epithelial cells were of mesenchymal
origin (Figure lh) and these are thought to be myofibro-
blasts.
Positive staining in epithelial cells with both C219 (21 of
29) and MRK16 (16 of 29) was detected in 1-9% of tumour
cells in all but one tumour. This confirms two previous
studies which found P-glycoprotein expression in one of nine
(Sugawara et al., 1988) and two of twelve (Schneider et al.,
1989) untreated breast cancers. The latter study considered
staining in isolated cells to be negative, but it may be these
cells which are selected following drug exposure, and are
responsible for the development of clinical drug resistance.
Our staining in epithelial cells was mostly membrane bound,
although some cytoplasmic staining was seen, and these cells
were confirmed as tumour cells by haematoxylin and eosin
staining of a separate section from each tumour.
A surprising finding was the demonstration of P-glyco-
protein immunoreactivity in stromal cells with both C219 (26
of 29) and MRK16 (12 of 29). The fact that stromal staining
has been detected by two monoclonal antibodies (Figure le
and f), which recognise different epitopes of P-glycoprotein,
suggests that it is genuine expression of the protein. Staining
in stromal cells has not previously been described in the
literature although we are aware that one other group has
detected expression in stromal cells by in situ hybridisation
(Fojo, personal communication). It has probably not been
recognised previously as other studies have often used human
breast cancer cell lines (Fairchild et al., 1987) or cytospin
preparations of breast cancer cell suspensions (Salmon et al.,
1989) to study P-glycoprotein expression. In all but one
tumour, the percentage of stromal cells staining was always
greater with C219 than with MRK16 (Table I). Recent
evidence has suggested that C219 may cross-react with the
heavy chain of myosin in skeletal and cardiac muscle (Thie-
baut et al., 1989). Since it is well recognised that scirrhous
carcinomas of the breast contain a population of stromal
cells with characteristics of myofibroblasts (Tremblay, 1979),
and that explants of these cancers give rise to outgrowths ofP-GLYCOPROTEIN AND BREAST CANCER 761
which > 90% are myofibroblasts (Barsky et al., 1984), it is
possible that our higher results with C219 are due to a
cross-reaction with myosin. Alternatively C219 may be recog-
nising a form of P-glycoprotein not detected by MRK16.
Previous studies with MRK16 have used formaldehyde
fixation before immunocytochemistry, as cells fixed with
acetone showed only weak localisation (Thiebaut et al.,
1987). It could be argued that this is one reason why our
positive staining was usually less with MRK16 in both
epithelial and stromal cells. However, we used acetone
fixation for both C219 and MRK16 as our staining with both
antibodies when present, was as distinct and as strong as our
positive controls. We believe acetone-fixation has been suc-
cessful with MRK16 in our study as the alkaline phosphatase
method is particularly sensitive when compared with other
immunohistochemical techniques.
The use of immunohistochemistry has allowed us to exam-
ine P-glycoprotein distribution within breast cancers and we
have found heterogeneity of expression. This technique is
extremely sensitive and can localise immunoreactivity in
small numbers of single cells, unlike measurement of mdr-1
mRNA in whole tumours (Fojo et al., 1987), which is less
sensitive and can give rise to erroneous results because of
tumour cell heterogeneity or expression in adjacent normal
tissue.
There appear to be two mechanisms whereby tumours can
become resistant to cytotoxic drugs. Either the resistant cells
are present before drug exposure and are merely selected out
with death of drug sensitive cells, or resistant cells arise de
novo following drug exposure. Our results support the former
theory for breast cancer and multidrug resistance. If this is
the case then the use of modulators in breast cancer would
be appropriate. The results of clinical trials in breast cancer
of modulators, e.g. quinidine, which can compete for binding
to P-glycoprotein with cytotoxic drugs such as adriamycin
(Yusa & Tsuruo, 1989) are awaited.
In conclusion, we have demonstrated P-glycoprotein ex-
pression in primary breast cancers with no prior exposure to
cytotoxic drugs. An interesting finding was expression in
both epithelial and stromal cells. As immunocytochemistry
can detect P-glycoprotein expression in single cells it is par-
ticularly useful where expression is heterogeneous, e.g. breast
cancer, where MDR cells, when present, may only comprise
a small percentage of the tumour cell population. It is hoped
that this technique can be used to identify tumours with
significant MDR expression so that MDR drugs can be
avoided in treatment schedules or so that MDR modulators
may be incorporated into the treatment of these tumours.
The authors wish to thank Jim Richmond for expert technical advice
and Margaret Jenkins for typing the manuscript.
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